Neuroendocrine tumour of the lung – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neuroendocrine tumour of the lung – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas https://clinicaltrials.eu/trial/comparing-tarlatamab-with-standard-chemotherapy-in-patients-with-pre-treated-advanced-pulmonary-or-gastroenteropancreatic-neuroendocrine-carcinomas/ Wed, 29 Apr 2026 15:06:22 +0000 https://clinicaltrials.eu/trial/comparing-tarlatamab-with-standard-chemotherapy-in-patients-with-pre-treated-advanced-pulmonary-or-gastroenteropancreatic-neuroendocrine-carcinomas/ This study focuses on patients with advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs) who have previously received treatment with platinum-based chemotherapy. The main treatment being investigated is tarlatamab, which will be compared to standard chemotherapy treatments including oxaliplatin, dacarbazine, docetaxel, temozolomide, irinotecan, and fluorouracil. Some patients may also receive immunotherapy medications like atezolizumab, nivolumab, or pembrolizumab.

The purpose of this research is to evaluate how well tarlatamab works compared to standard chemotherapy treatments in treating this type of cancer. The study will measure how long patients survive after receiving treatment. The medication will be given through an infusion into a vein.

During the study, doctors will monitor patients’ response to treatment using imaging scans and blood tests. They will also track any side effects that occur and evaluate patients’ quality of life using questionnaires. The study is expected to last for approximately 24 months per patient.

]]> Study on Durvalumab, Etoposide, and Platinum Drug Combination for First-Line Treatment of Advanced Large-Cell Neuroendocrine Lung Cancer Patients https://clinicaltrials.eu/trial/study-on-durvalumab-etoposide-and-platinum-drug-combination-for-first-line-treatment-of-advanced-large-cell-neuroendocrine-lung-cancer-patients/ Wed, 29 Apr 2026 14:47:47 +0000 https://clinicaltrials.eu/trial/study-on-durvalumab-etoposide-and-platinum-drug-combination-for-first-line-treatment-of-advanced-large-cell-neuroendocrine-lung-cancer-patients/ This clinical trial is focused on studying a type of lung cancer known as Large-Cell Neuroendocrine Carcinoma (LCNEC). This cancer can be in an advanced stage, either locally advanced or metastatic, meaning it has spread to other parts of the body. The study is investigating the effectiveness and safety of a treatment combination that includes the drug Durvalumab (also known by its code name MEDI 4736), along with two chemotherapy drugs, Etoposide and a type of platinum-based drug, which can be either Cisplatin or Carboplatin. These medications are given as an infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of this study is to determine how well this combination of drugs works as a first-line treatment, which means it is the first treatment given for this type of cancer. Participants in the study will receive these medications over a period of time, and their health will be monitored to see how the cancer responds to the treatment. The study aims to find out if this combination can help control the cancer and improve the quality of life for patients with LCNEC.

Throughout the study, participants will receive regular check-ups and assessments to track their progress and any side effects they might experience. The study will also look at how long the treatment can keep the cancer from getting worse. This information will help doctors understand if this treatment combination is a good option for patients with advanced LCNEC.

]]> Study of 68Ga Satoreotide Trizoxetan PET/CT in Patients with High-Grade Neuroendocrine Lung Cancer https://clinicaltrials.eu/trial/study-of-68ga-satoreotide-trizoxetan-pet-ct-in-patients-with-high-grade-neuroendocrine-lung-cancer/ Wed, 29 Apr 2026 14:24:22 +0000 https://clinicaltrials.eu/trial/study-of-68ga-satoreotide-trizoxetan-pet-ct-in-patients-with-high-grade-neuroendocrine-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as high-grade neuroendocrine lung cancer, which includes large cell neuroendocrine lung cancer and small cell lung cancer. The study is investigating a new imaging method using a special tracer called 68Ga-satoreotide trizoxetan. This tracer is used in a type of scan called positron emission tomography or PET scan, which helps doctors see how the cancer is behaving inside the body.

The purpose of the study is to see how well the 68Ga-satoreotide trizoxetan tracer is taken up by cancer cells in patients with these types of lung cancer. During the study, patients will receive an injection of the tracer, and then undergo a PET/CT scan. This scan combines the PET scan with a computed tomography or CT scan, providing detailed images of the cancer. The study will compare these images to previous scans to see if the new tracer can identify cancerous areas more effectively.

The study will also measure certain parameters in the cancerous areas, such as how much of the tracer is absorbed, and compare these measurements to those in normal organs like the lung, kidney, and liver. This will help researchers understand how well the tracer can distinguish between cancerous and non-cancerous tissues. The study is expected to continue until mid-2026.

]]> Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus https://clinicaltrials.eu/trial/study-comparing-177lu-edotreotide-and-everolimus-for-patients-with-neuroendocrine-tumors-in-the-lung-and-thymus/ Wed, 29 Apr 2026 14:23:55 +0000 https://clinicaltrials.eu/trial/study-comparing-177lu-edotreotide-and-everolimus-for-patients-with-neuroendocrine-tumors-in-the-lung-and-thymus/ This clinical trial is focused on studying the effectiveness and safety of treatments for patients with neuroendocrine tumors of the lung and thymus. These are a type of cancer that can occur in the hormone-producing cells of the lung and thymus. The study will compare two treatments: 177Lu-Edotreotide, a solution for injection or infusion, and Afinitor (everolimus), which is taken as a tablet. The purpose of the study is to see how well these treatments work in stopping the cancer from getting worse and to understand their safety and how they affect patients’ quality of life.

Participants in the study will receive either 177Lu-Edotreotide or Afinitor. 177Lu-Edotreotide is given through an intravenous infusion, which means it is delivered directly into the bloodstream. Afinitor is taken orally as a tablet. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will last for a period of time, during which participants will be monitored regularly to assess the progression of their disease and any side effects they may experience.

The main goal of the study is to determine how long the treatments can prevent the cancer from progressing, which is known as progression-free survival. This will be measured from the time participants start the study until their disease shows signs of getting worse or they pass away. The study will also collect information on how the treatments impact the participants’ daily lives and overall well-being. This information will help doctors understand which treatment might be more beneficial for patients with neuroendocrine tumors of the lung and thymus.

]]>